Do you utilize MammaPrint testing to determine whether or not to offer neoadjuvant chemotherapy for high-risk ER+ breast cancer?  

Outside of T3/T4 or N2/3 disease, high-risk ER-positive breast cancers are hard to be ascertained without doing genomic assays.We do have published data supporting the use of both MammaPrint and Oncotype performed on Core Bx to guide us on neoadjuvant endocrine therapy versus chemotherapy. Two ...

Yes, MammaPrint is a genomic test that can be used to identify ER+ patients who benefit from adjuvant chemotherapy. If a patient is predicted to benefit from adjuvant chemotherapy, she will also benefit to the same extent if she receives the treatment preoperatively.Preoperative administration may b...

It’s reasonable to use a genomic assay to determine whether patients with localized (T1-3N0-1) HR+HER2- breast cancer would derive benefit from neoadjuvant chemotherapy. Mammoprint is a prognostic and somewhat predictive test that may have utility in these cases. Data suggests it is best used ...